Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAFTADINE vs BEPOTASTINE BESILATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Bepotastine besilate is a selective histamine H1 receptor antagonist that inhibits histamine release from mast cells and reduces eosinophil chemotaxis, thereby suppressing allergic inflammatory responses.
FDA: Prevention of itching associated with allergic conjunctivitis,Off-label: No established off-label uses
Allergic conjunctivitis (FDA approved),Allergic rhinitis (off-label),Urticaria (off-label)
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
2 mg/m L ophthalmic solution: 1 drop in each affected eye twice daily.
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Terminal elimination half-life is approximately 9-10 hours in healthy adults, allowing twice-daily dosing for allergic conjunctivitis.
Not extensively metabolized; primarily excreted unchanged in urine. Cytochrome P450 metabolism is minimal.
Primarily metabolized via glucuronidation (UGT1A9, UGT2B7) and oxidation (CYP3A4 minor pathway).
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Primarily renal excretion as unchanged drug (~75-80% of dose) with minor fecal elimination (~10-15%).
Approximately 40% bound to plasma proteins.
Approximately 55-60% bound to human plasma proteins, primarily albumin.
Vd is approximately 1.4 L/kg, indicating distribution beyond plasma into extravascular tissues.
Following oral administration, Vd is 1.4-1.8 L/kg, indicating extensive tissue distribution. Not applicable for ophthalmic use.
Systemic bioavailability after topical ocular administration is low (estimated < 0.5%) due to dilution, local metabolism, and limited corneal penetration.
Oral bioavailability is <1% due to extensive first-pass metabolism. Ophthalmic: Systemic absorption negligible (<0.5%).
No dose adjustment required for any degree of renal impairment.
No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment required for any degree of hepatic impairment.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Children 2 years and older: same as adult dose. Safety and efficacy in children under 2 years not established.
≥2 years: same as adult dose (1 drop in each affected eye twice daily).
No specific dose adjustment needed; use same dose as for younger adults.
No dose adjustment required; same as adult dosing.
None
None.
Do not inject; for topical ophthalmic use only,Avoid wearing contact lenses if eyes are red,May cause temporary blurred vision after instillation,Use with caution in patients with known hypersensitivity
May cause severe hypersensitivity reactions (angioedema, bronchospasm).,Avoid use in patients with known hypersensitivity to bepotastine.,Ophthalmic use: do not wear contact lenses during treatment; may cause transient burning/stinging.,Systemic use: caution in patients with renal impairment (dose adjustment required).,Avoid concurrent use with CNS depressants due to additive sedative effects.
Hypersensitivity to alcaftadine or any component of the formulation
Hypersensitivity to bepotastine or any component of the formulation.,Severe renal impairment (Cr Cl <30 m L/min) for systemic use.
No specific food interactions reported. As an ophthalmic preparation, systemic absorption is minimal and unlikely to be affected by food.
No clinically significant food interactions reported with ophthalmic use.
Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, alcaftadine should be used during pregnancy only if clearly needed.
Bepotastine besilate is not recommended during pregnancy. Animal studies have shown no teratogenic effects at doses up to 200 mg/kg/day in rats (approximately 200 times the human clinical dose) and 100 mg/kg/day in rabbits (approximately 200 times the human clinical dose), but there are no adequate and well-controlled studies in pregnant women. During the first trimester, the risk is unknown; during the second and third trimesters, potential risks to the fetus cannot be excluded.
It is not known whether alcaftadine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when alcaftadine is administered to a nursing woman. The M/P ratio has not been established.
It is not known whether bepotastine besilate is excreted in human milk. In rat studies, drug-related material was detected in milk following oral administration. Because many drugs are excreted in human milk, caution should be exercised when bepotastine besilate is administered to a nursing woman. The milk-to-plasma (M/P) ratio has not been established for humans. Breastfeeding is not recommended during treatment.
No pharmacokinetic studies have been performed in pregnant women. Based on the available animal data and the low systemic exposure after ocular administration, no dosing adjustment is recommended during pregnancy.
No dose adjustments are recommended for pregnant women based on current pharmacokinetic data. However, systemic absorption after ophthalmic administration is minimal, and no pregnancy-specific pharmacokinetic studies have been conducted. Use caution and prescribe only if clearly needed.
ALCAFTADINE is a topical ophthalmic antihistamine and mast cell stabilizer used for allergic conjunctivitis. Administer one drop twice daily in each affected eye. Onset of action is within minutes. Contraindicated in patients with hypersensitivity to any component. Use with caution in contact lens wearers; remove lenses before instillation and wait 10 minutes before reinserting. Do not touch dropper tip to any surface to avoid contamination.
Bepotastine besilate is a selective histamine H1 receptor antagonist used topically for allergic conjunctivitis. Avoid use with contact lenses; remove before instillation and wait at least 10 minutes before reinserting. Systemic absorption is minimal, but caution in patients with severe hepatic impairment. Onset of action is within 15 minutes, duration 8 hours. Do not touch dropper tip to eye or surrounding surfaces.
Do not wear contact lenses if your eyes are red; after the redness subsides, wait at least 10 minutes after instilling the drop before reinserting lenses.,Do not touch the dropper tip to your eye or any surface to avoid contamination.,Wait at least 5 minutes between using this drug and other eye drops.,If you miss a dose, use it as soon as you remember; if it is almost time for the next dose, skip the missed dose and resume your regular schedule.,Do not use more than prescribed; overuse may cause eye irritation.,Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Wash hands before and after use.
Wash hands before use.,Tilt head back, pull lower eyelid down, and instill one drop in the affected eye(s) twice daily.,Do not touch the dropper tip to your eye or any surface.,Remove contact lenses before use and wait at least 10 minutes before reinserting.,Do not use if solution changes color or becomes cloudy.,Common side effects include mild eye irritation, bitter taste, or headache.,If you experience eye pain, vision changes, or redness, contact your doctor.
"Dextroamphetamine, a central nervous system stimulant, may reduce the sedative effects of Alcaftadine, an antihistamine used for allergic conjunctivitis, by opposing its central histamine H1 receptor blockade. This pharmacodynamic antagonism can lead to diminished sedation and potentially decreased therapeutic efficacy of Alcaftadine for its intended ocular antiallergic effects. Patients may experience reduced symptom relief and increased ocular discomfort."
"Hydroxyamphetamine may decrease the sedative activities of Alcaftadine."
"Phentermine may decrease the sedative activities of Alcaftadine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAFTADINE vs BEPOTASTINE BESILATE, answered by our medical review team.
ALCAFTADINE is a Ophthalmic Antihistamine that works by Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.. BEPOTASTINE BESILATE is a Ophthalmic Antihistamine that works by Bepotastine besilate is a selective histamine H1 receptor antagonist that inhibits histamine release from mast cells and reduces eosinophil chemotaxis, thereby suppressing allergic inflammatory responses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAFTADINE and BEPOTASTINE BESILATE depend on the specific clinical indication. These are both Ophthalmic Antihistamine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAFTADINE is: 1 drop of 0.25% ophthalmic solution in each affected eye twice daily.. The standard adult dose of BEPOTASTINE BESILATE is: 2 mg/m L ophthalmic solution: 1 drop in each affected eye twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAFTADINE and BEPOTASTINE BESILATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAFTADINE is classified as Category C. Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate a. BEPOTASTINE BESILATE is classified as Category C. Bepotastine besilate is not recommended during pregnancy. Animal studies have shown no teratogenic effects at doses up to 200 mg/kg/day in rats (approximately 200 times the human c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.